Showing results (1-10 of 12) with videos related to
Sort By:
Pageof 2
Journal of Hepatology|September 17, 2022
Loss of liver function in chronic liver disease: An identity crisisCarmen Berasain, Maria Arechederra, Josepmaria Argemí, et al.Cancers|September 13, 2025
Immune-Checkpoint Inhibitors for Biliary Tract Cancer: Who Benefits and What Is Next?Lucía Ceniceros, Manuel de La Torre, Ana Landa Magdalena, et al.Antioxidants (Basel, Switzerland)|November 18, 2020
Antioxidant Lifestyle, Co-Morbidities and Quality of Life Empowerment Concerning Liver FibrosisDiego Martinez-Urbistondo, Rafael Suarez Del Villar, Josepmaria Argemí, et al.Journal of Cell Science|August 11, 2017
Iron affects Ire1 clustering propensity and the amplitude of endoplasmic reticulum stress signalingNir Cohen, Michal Breker, Anush Bakunts, et al.JHEP Reports : Innovation in Hepatology|October 10, 2025
Isolation and immortalization of human portal vein endothelial cells: A novel research tool for studying splanchnic vasculatureAina Anton, Sarah Shalaby, Júlia Campalans, et al.Journal for Immunotherapy of Cancer|October 21, 2025
Pan-microbial serological repertoire as a biomarker of immunotherapy response in hepatocellular carcinomaShay Behrens, Whitney Leet Do, Limin Wang, et al.Gastroenterology|January 14, 2017
X-box Binding Protein 1 Regulates Unfolded Protein, Acute-Phase, and DNA Damage Responses During Regeneration of Mouse LiverJosepmaria Argemí, Theresia R Kress, Haisul C Y Chang, et al.Journal for Immunotherapy of Cancer|November 30, 2022
Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm studyManuel de la Torre-Aláez, Ana Matilla, Maria Varela, et al.Oncoimmunology|March 19, 2026
Immunogenicity of neoantigens from hepatocellular carcinoma patients treated with a combined radioimmunotherapyBelén Aparicio, Leyre Silva, Marta Ruiz, et al.Journal of Patient-Reported Outcomes|April 8, 2025
Health-related quality of life in patients with unresectable hepatocellular carcinoma treated with SIRT and nivolumab: a sub-analysis of the NASIR-HCC trialManuel De la Torre-Aláez, Ana Matilla, María Varela, et al.Pageof 2